Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News
SYS-CON.TV
Cloud Expo & Virtualization 2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Cloud Computing & Enterprise IT: Cost & Operational Benefits
How and Why is a Flexible IT Infrastructure the Key To the Future?
Click For 2008 West
Event Webcasts
Sets up US subsidiary

YORK, UK -- (Marketwire) -- 11/26/12 --






          Tissue Regenix sets up United States subsidiary
           to target growing regenerative medicine market

Tissue Regenix appoints Greg Bila President, Tissue Regenix USA

YORK, 26 November 2012. Tissue Regenix Group plc ('Tissue Regenix') has
set up a subsidiary company in the United States, as part of its
commercialisation strategy for its dCELL® technology platform.

Tissue Regenix is also pleased to announce the recruitment of Greg Bila
from Kinetic Concepts Inc. ('KCI') as President of Tissue Regenix USA.
Greg's recent career at KCI has spanned a number of sales & marketing
roles and brings over 20 years' experience in pharmaceutical and
medical device fields.

Tissue Regenix will use its patented dCELL® technology to target a
number of areas. Work will focus initially on applying the dCELL® to
the treat a number of chronic diseases but, over time, could be
developed for other applications including vascular repair, heart valve
replacement and knee repair. Tissue Regenix's dCELL® technology have
delivered encouraging interim data.

Antony Odell, Managing Director of Tissue Regenix commented: "This is a
significant step in the development of Tissue Regenix. It is an
excellent signal of the strength of TR's proposition that we can
attract people of Greg's calibre and experience, we look forward to
advancing our plans in the US with him at the helm. The United States
presents an opportunity to establish our platform dCELL® technology in
a market potentially worth hundreds of millions of dollars."

Greg Bila, President of Tissue Regenix Wound Care Inc. said: "I am
excited to be able to join Tissue Regenix at the beginning of its
expansion into the United States. TR's dCELL® technology will be a
welcome offering for the treatment of number of diseases and the
potential indications are attractive."

The potential advantages of the Company's dCELL technology over other
types of decellularised tissue scaffolds was underpinned at Tissue
Regenix technology day in October by Dr Alan Dardik, Associate
Professor of Surgery at Yale University, who has conducted pre-clinical
studies of Tissue Regenix dCELL® vascular patch and published the
results in the scientific journal PLoS ONE.

Speaking about those studies Dr Dardik commented: "I have to say my
impression is it's the closest thing on the market to a tissue
engineered patch. It's the next technology. Other companies are trying
to attract stem-cells but they've already got the stem cells that are
coming into their patch."



ENDS


For Further Information

Tissue Regenix Group plc:         01904 435 176
Antony Odell

Newgate Communications:
Alistair Kellie                   07801 234598
Andrew Adie                       07970 256512
Martin Greig                      07584 221513





About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. The company's patented decellularisation
('dCELL®) technology removes DNA and other cellular material from
animal and human tissue leaving an acellular tissue scaffold which is
not rejected by the patient's body which can then be used to repair
diseased or worn out body parts. The potential applications of this
process are diverse and address many critical clinical needs such as
vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.



                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts:
RNS
Customer
Services
0044-207797-4400
Email Contact
http://www.rns.com

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Cloud Developer Stories
Leysin American School is an exclusive, private boarding school located in Leysin, Switzerland. Leysin selected an OpenStack-powered, private cloud as a service to manage multiple applications and provide development environments for students across the institution. Seeking to m...
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy...
We are all here because we are sold on the transformative promise of The Cloud. But what good is all of this ephemeral, on-demand infrastructure if your usage doesn't actually improve the agility and speed of your business? How must Operations adapt in order to avoid stifling you...
The definition of IoT is not new, in fact it’s been around for over a decade. What has changed is the public's awareness that the technology we use on a daily basis has caught up on the vision of an always on, always connected world. If you look into the details of what comprises...
Software-driven innovation is becoming a primary approach to how businesses create and deliver new value to customers. A survey of 400 business and IT executives by the IBM Institute for Business Value showed businesses that are more effective at software delivery are also more p...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021



SYS-CON Featured Whitepapers
ADS BY GOOGLE